News

『栄養と料理』2021年2月号 「栄養Watch」参考文献一覧

参考・引用文献

『栄養と料理』2021年2月号 p108~109 栄養watch 参考文献一覧

 

(1)Alter HJ, et al.: Reflections on the History of HCV: A Posthumous Examination. Clin Liver Dis. 15(Suppl 1): S64–S71 (2020)

(2)Houghton M.: Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harb Perspect Med. 9(12): a037069 (2019)

(3)Rice CM, et al.: Hepatitis C: Treatment triumphs. Nature. 510(7503): 43-44 (2014)

(4)Takahashi M, et al.: High Prevalence of Antibodies to Hepatitis A and E Viruses and Viremia of Hepatitis B, C, and D Viruses among Apparently Healthy Populations in Mongolia. Clin Diag Lab Immunol. 11(2): 392-398 (2004)

(5)Foster GR, et al.: Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 373(27): 2608-2617 (2015)

(6)日本肝臓学会編:C型肝炎治療ガイドライン(第8版).(2020)

(7)加藤眞三,鈴木和子,大木いづみ:慢性肝炎・肝硬変の安心ごはん──肝臓がんを防ぐために.女子栄養大学出版部.(2014)

(8)星野博美:HCVキャリアにおける肝の病態および治療と血清鉄マーカーの関連性.女子栄養大学修士論文.(2004)

(9)Muto Y, et al.: Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 35(3): 204–214 (2006)

(10)Kawaguchi Y, et al.: Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol. 20(11): 2888-2901 (2014)

(11)Sadeghi A, et al.: Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 75(11): 3379-3385 (2020)

(12)Eslami G, et al.: The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 75(11):3366-3372 (2020)